DUBLIN--(BUSINESS WIRE)--The "Denosumab (Prolia & Xgeva) Biosimilars Pipeline Review" report has been added to ResearchAndMarkets.com's offering. Denosumab biosimilars, which are currently under ...
Treatment strategies after denosumab discontinuation in non-metastatic breast cancer treated with AI
Aromatase inhibitors (AIs) are a cornerstone of adjuvant therapy for hormone receptor–positive breast cancer, significantly reducing recurrence and mortality. However, by suppressing estrogen ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results